News

Keryx Biopharma has presented the data in the pediatric solid tumor poster discussion session held at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO)

VBL claimed that VB-201 is the first in a new class of drugs and the lead candidate of several proprietary phospholipid analogs from its proprietary Lecinoxoid family that

Illumina said that the application flexibility, ease of use and scalability of the HiSeq 2000 enables a wide range of biomedical applications. The compatibility of HiSeq 2000 sample

The results of the study were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting as part of an ASCO-sponsored press briefing. Eisai said that the

Opal Therapeutics is an immunotherapy development company focusing on novel therapies for HIV and Hepatitis C (HCV) based on proprietary technology licensed from the University of Melbourne. The

Benlysta is an investigational human monoclonal antibody drug. It is the first in a new class of drugs called BLyS-specific inhibitors that recognise and inhibit the biological activity

Marc Mansour, vice president of R&D at Immunovaccine, said: “Vaxil has an approach for identifying cancer antigens that get presented more efficiently by the MHC molecules. Vaxil’s long

Under this partnership, a portion of the on-campus molecular tracer laboratories of UW’s department of radiology will be relocated including one operated by John Grierson, who developed the

Ascenta Therapeutics and sanofi-aventis said that these orally-active, small-molecule drug candidates remove a block to normal p53 tumor suppressor function and inhibit the interaction between HDM2 (Human Double